Therapeutically, interventional human evidence now supports immunity as both driver and target: anti-VEGF re-seals leaky barriers, complement inhibition slows geographic atrophy, steroid implants suppress inflammatory oedema, and anti-TNF/IL-6R biologics improve refractory uveitis. The gene discussed is VEGFA; the disease is atrophic macular degeneration.